Report Id: PLBM0320
Liquid Biopsy Market Size By Application (Non-Cancer Applications, Cancer Applications), By End User (Academic and Research Centers, Hospitals and Physician Laboratories, Reference Laboratories, Other End Users), By Clinical Application (Early Cancer Screening, Recurrence Monitoring, Treatment Monitoring, Therapy Selection), By Product and Service (Instruments, Services, Assay Kits), By Circulating Biomarker (Extracellular Vesicles, Circulating Tumor Cells, Circulating Tumor Dna, Cell-Free Dna, Other Circulating Biomarkers), By Technology (Single Gene Analysis Using Pcr Microarrays, Multi-Gene-Parallel Analysis Using Ngs), By Region (North America, Europe, Asia-Pacific, Rest of the World), Market Analysis Report, Forecast 2023-2028
Liquid biopsy is a complicated cancer diagnostic assay administered using biofluids like blood, CSF, plasma and urine for cancer detection. Liquid biopsy test is often wont to detect cancer in early stages.
COVID-19 Impact Analysis Report
"Get Latest Updated Reports as per the COVID-19 Impact"
Infopedia: Access Our All Reports Online at Affordable Price
CLICK HEREMARKET SNAPSHOT
Major Players
- Mdxhealth SA
- Genomic Health Inc
- Raindance Technologies Inc
- Thermo Fisher Scientific Inc
- Illumina Inc
Study period:
Fastest Growing Market:
2023-2028
APAC
Base Year:
Largest Market:
2022
North America
CAGR:
6
REPORT DESCRIPTION
A liquid biopsy is fast ahead traction as a supplement or alternate to doing a tissue biopsy for applications in procreative health, cancer, and transplant medicine. The liquid biopsy techniques agree the physicians to comprehend the critical nature of the disease after the finding and screening procedure. The main biomarker kinds used in liquid biopsy contain circulating cell-free nucleic acids. Extracellular vesicles are a varied class of lipid-bound elements shed by any cell in the body in pathological and physiological conditions. Microarray technology has been widely used in cancer research for more than a period. Droplet Digital PCR agrees for the detection of target sequences which are contemporary in the very low background against other sequences present at high concentrations. Proteomics platforms include Mass Spectrometry and biochips. Deficiency of consensus on Standard Operating Measures and poor compensation structures are some of the main factors hindering the global liquid biopsy market. The compensation and treatment monitoring for liquid biopsy is limited, and it is achieved in a few laboratories. The poor reimbursement system is a important restraint which restricts the individuals to go for cancer detection tests and affects cancer biomarkers market negatively.
The global Liquid Biopsy market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Liquid Biopsy market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.
Competitive Rivalry
Mdxhealth SA, Genomic Health, Inc., Raindance Technologies, Inc, Thermo Fisher Scientific Inc., Illumina, Inc., Biocept, Inc, Qiagen N.V., Roche Diagnostics, Bio-Rad Laboratories, Inc., Myriad Genetics, Inc, and others are among the major players in the global Liquid Biopsy market. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.
The Liquid Biopsy Market has been segmented as below:
Liquid Biopsy Market, By Application
- Non-Cancer Applications
- Cancer Applications
Liquid Biopsy Market, By End User
- Academic and Research Centers
- Hospitals and Physician Laboratories
- Reference Laboratories
- Other End Users
Liquid Biopsy Market, By Clinical Application
- Early Cancer Screening
- Recurrence Monitoring
- Treatment Monitoring
- Therapy Selection
Liquid Biopsy Market, By Product and Service
- Instruments
- Services
- Assay Kits
Liquid Biopsy Market, By Circulating Biomarker
- Extracellular Vesicles
- Circulating Tumor Cells
- Circulating Tumor Dna
- Cell-Free Dna
- Other Circulating Biomarkers
Liquid Biopsy Market, By Technology
- Single Gene Analysis Using Pcr Microarrays
- Multi-Gene-Parallel Analysis Using Ngs
Liquid Biopsy Market, By Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
Liquid Biopsy Market, By Company
- Mdxhealth SA
- Genomic Health, Inc.
- Raindance Technologies, Inc
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Biocept, Inc
- Qiagen N.V.
- Roche Diagnostics
- Bio-Rad Laboratories, Inc.
- Myriad Genetics, Inc
- Menarini-Silicon Biosystems
- Trovagene, Inc.
- Guardant Health, Inc.
The report covers:
- Global Liquid Biopsy market sizes from 2022 to 2028, along with CAGR for 2023-2028
- Market size comparison for 2022 vs 2028, with actual data for 2022, estimates for 2023 and forecast from 2024 to 2028
- Global Liquid Biopsy market trends, covering comprehensive range of consumer trends & manufacturer trends
- Value chain analysis covering participants from raw material suppliers to the downstream buyer in the global Liquid Biopsy market
- Major market opportunities and challenges in forecast timeframe to be focused
- Competitive landscape with analysis on competition pattern, portfolio comparisons, development trends and strategic management
- Comprehensive company profiles of the key industry players
Report Scope:
The global Liquid Biopsy market report scope includes detailed study covering underlying factors influencing the industry trends.
The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.
The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Liquid Biopsy market share. Major industry players with significant revenue share include Mdxhealth SA, Genomic Health, Inc., Raindance Technologies, Inc, Thermo Fisher Scientific Inc., Illumina, Inc., Biocept, Inc, Qiagen N.V., Roche Diagnostics, Bio-Rad Laboratories, Inc., Myriad Genetics, Inc, and others.
Reasons to Buy this Report:
- Gain detailed insights on the Liquid Biopsy industry trends
- Find complete analysis on the market status
- Identify the Liquid Biopsy market opportunities and growth segments
- Analyse competitive dynamics by evaluating business segments & product portfolios
- Facilitate strategy planning and industry dynamics to enhance decision making
Some of the recent developments in Liquid Biopsy Market are as follows:
Mdxhealth SA
- 10-2019: MDxHealth is a multinational healthcare company which offers actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer.
- 27-2018: MDxHealth SA declared the publication of positive data demonstrating the value of the SelectMDx liquid biopsy test for Prostate Cancer in guiding patient management for men being considered for multiparametric MRI and the clinical utility in guiding biopsy decisions in real-world clinical practice.
Genomic Health, Inc.
- 09-2014: Genomic Health, Inc. declared positive results from its first two feasibility studies assessing multiple technologies, including next-generation sequencing, for their ability to detect and characterize the presence of bladder cancer DNA in urine and breast cancer DNA in blood.
- 11-2016: Genomic Health, Inc. declared plans to launch its first liquid biopsy test.
Customization
Customized report as per the requirement can be offered with appropriate recommendations.
Below are our New Reports :-
Connected Drug Delivery Devices Market
1. Introduction
1.1 Key Insights
1.2 Report Overview
1.3 Markets Covered
1.4 Stakeholders
2. Research Methodology
2.1 Research Scope
2.2 Market Research Process
2.3 Research Data Analysis
2.4.1 Secondary Research
2.4.2 Primary Research
2.4.3 Models for Estimation
2.5 Market Size Estimation
2.5.1 Bottom-Up Approach - Segmental Market Analysis
2.5.2 Top-Down Approach - Parent Market Analysis
3. Executive Summary
4. Market Overview
4.1 Introduction
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Challenges
4.2 Porter's Five Force Analysis
5. Liquid Biopsy Market, By Application
5.1 Introduction
5.2 Non-Cancer Applications
5.2.1 Market Overview
5.2.2 Market Size and Forecast
5.3 Cancer Applications
5.3.1 Market Overview
5.3.2 Market Size and Forecast
6. Liquid Biopsy Market, By End User
6.1 Introduction
6.2 Academic and Research Centers
6.2.1 Market Overview
6.2.2 Market Size and Forecast
6.3 Hospitals and Physician Laboratories
6.3.1 Market Overview
6.3.2 Market Size and Forecast
6.4 Reference Laboratories
6.4.1 Market Overview
6.4.2 Market Size and Forecast
6.5 Other End Users
6.5.1 Market Overview
6.5.2 Market Size and Forecast
7. Liquid Biopsy Market, By Clinical Application
7.1 Introduction
7.2 Early Cancer Screening
7.2.1 Market Overview
7.2.2 Market Size and Forecast
7.3 Recurrence Monitoring
7.3.1 Market Overview
7.3.2 Market Size and Forecast
7.4 Treatment Monitoring
7.4.1 Market Overview
7.4.2 Market Size and Forecast
7.5 Therapy Selection
7.5.1 Market Overview
7.5.2 Market Size and Forecast
8. Liquid Biopsy Market, By Product and Service
8.1 Introduction
8.2 Instruments
8.2.1 Market Overview
8.2.2 Market Size and Forecast
8.3 Services
8.3.1 Market Overview
8.3.2 Market Size and Forecast
8.4 Assay Kits
8.4.1 Market Overview
8.4.2 Market Size and Forecast
9. Liquid Biopsy Market, By Circulating Biomarker
9.1 Introduction
9.2 Extracellular Vesicles
9.2.1 Market Overview
9.2.2 Market Size and Forecast
9.3 Circulating Tumor Cells
9.3.1 Market Overview
9.3.2 Market Size and Forecast
9.4 Circulating Tumor Dna
9.4.1 Market Overview
9.4.2 Market Size and Forecast
9.5 Cell-Free Dna
9.5.1 Market Overview
9.5.2 Market Size and Forecast
9.6 Other Circulating Biomarkers
9.6.1 Market Overview
9.6.2 Market Size and Forecast
10. Liquid Biopsy Market, By Technology
10.1 Introduction
10.2 Single Gene Analysis Using Pcr Microarrays
10.2.1 Market Overview
10.2.2 Market Size and Forecast
10.3 Multi-Gene-Parallel Analysis Using Ngs
10.3.1 Market Overview
10.3.2 Market Size and Forecast
11. Liquid Biopsy Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 North America Liquid Biopsy, By Application
11.2.2 North America Liquid Biopsy, By End User
11.2.3 North America Liquid Biopsy, By Clinical Application
11.2.4 North America Liquid Biopsy, By Product and Service
11.2.5 North America Liquid Biopsy, By Circulating Biomarker
11.2.6 North America Liquid Biopsy, By Technology
11.3 Europe
11.3.1 Europe Liquid Biopsy, By Application
11.3.2 Europe Liquid Biopsy, By End User
11.3.3 Europe Liquid Biopsy, By Clinical Application
11.3.4 Europe Liquid Biopsy, By Product and Service
11.3.5 Europe Liquid Biopsy, By Circulating Biomarker
11.3.6 Europe Liquid Biopsy, By Technology
11.4 Asia-Pacific
11.4.1 Asia-Pacific Liquid Biopsy, By Application
11.4.2 Asia-Pacific Liquid Biopsy, By End User
11.4.3 Asia-Pacific Liquid Biopsy, By Clinical Application
11.4.4 Asia-Pacific Liquid Biopsy, By Product and Service
11.4.5 Asia-Pacific Liquid Biopsy, By Circulating Biomarker
11.4.6 Asia-Pacific Liquid Biopsy, By Technology
11.5 Rest of the World
11.5.1 Rest of the World Liquid Biopsy, By Application
11.5.2 Rest of the World Liquid Biopsy, By End User
11.5.3 Rest of the World Liquid Biopsy, By Clinical Application
11.5.4 Rest of the World Liquid Biopsy, By Product and Service
11.5.5 Rest of the World Liquid Biopsy, By Circulating Biomarker
11.5.6 Rest of the World Liquid Biopsy, By Technology
12. Competitive Insights
12.1 Key Insights
12.2 Company Market Share Analysis
12.3 Strategic Outlook
12.3.1 Mergers & Acquisitions
12.3.2 New Product Development
12.3.3 Portfolio/Production Capacity Expansions
12.3.4 Joint Ventures, Collaborations, Partnerships & Agreements
12.3.5 Others
13. Company Profiles
13.1 Mdxhealth SA
13.1.1 Company Overview
13.1.2 Product/Service Landscape
13.1.3 Financial Overview
13.1.4 Recent Developments
13.2 Genomic Health, Inc.
13.2.1 Company Overview
13.2.2 Product/Service Landscape
13.2.3 Financial Overview
13.2.4 Recent Developments
13.3 Raindance Technologies, Inc
13.3.1 Company Overview
13.3.2 Product/Service Landscape
13.3.3 Financial Overview
13.3.4 Recent Developments
13.4 Thermo Fisher Scientific Inc.
13.4.1 Company Overview
13.4.2 Product/Service Landscape
13.4.3 Financial Overview
13.4.4 Recent Developments
13.5 Illumina, Inc.
13.5.1 Company Overview
13.5.2 Product/Service Landscape
13.5.3 Financial Overview
13.5.4 Recent Developments
13.6 Biocept, Inc
13.6.1 Company Overview
13.6.2 Product/Service Landscape
13.6.3 Financial Overview
13.6.4 Recent Developments
13.7 Qiagen N.V.
13.7.1 Company Overview
13.7.2 Product/Service Landscape
13.7.3 Financial Overview
13.7.4 Recent Developments
13.8 Roche Diagnostics
13.8.1 Company Overview
13.8.2 Product/Service Landscape
13.8.3 Financial Overview
13.8.4 Recent Developments
13.9 Bio-Rad Laboratories, Inc.
13.9.1 Company Overview
13.9.2 Product/Service Landscape
13.9.3 Financial Overview
13.9.4 Recent Developments
13.10 Myriad Genetics, Inc
13.10.1 Company Overview
13.10.2 Product/Service Landscape
13.10.3 Financial Overview
13.10.4 Recent Developments
13.11 Menarini-Silicon Biosystems
13.11.1 Company Overview
13.11.2 Product/Service Landscape
13.11.3 Financial Overview
13.11.4 Recent Developments
13.12 Trovagene, Inc.
13.12.1 Company Overview
13.12.2 Product/Service Landscape
13.12.3 Financial Overview
13.12.4 Recent Developments
13.13 Guardant Health, Inc
13.13.1 Company Overview
13.13.2 Product/Service Landscape
13.13.3 Financial Overview
13.13.4 Recent Developments
The Liquid Biopsy Market has been segmented as below:
Liquid Biopsy Market, By Application
- Non-Cancer Applications
- Cancer Applications
Liquid Biopsy Market, By End User
- Academic and Research Centers
- Hospitals and Physician Laboratories
- Reference Laboratories
- Other End Users
Liquid Biopsy Market, By Clinical Application
- Early Cancer Screening
- Recurrence Monitoring
- Treatment Monitoring
- Therapy Selection
Liquid Biopsy Market, By Product and Service
- Instruments
- Services
- Assay Kits
Liquid Biopsy Market, By Circulating Biomarker
- Extracellular Vesicles
- Circulating Tumor Cells
- Circulating Tumor Dna
- Cell-Free Dna
- Other Circulating Biomarkers
Liquid Biopsy Market, By Technology
- Single Gene Analysis Using Pcr Microarrays
- Multi-Gene-Parallel Analysis Using Ngs
Liquid Biopsy Market, By Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
Liquid Biopsy Market, By Company
- Mdxhealth SA
- Genomic Health, Inc.
- Raindance Technologies, Inc
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Biocept, Inc
- Qiagen N.V.
- Roche Diagnostics
- Bio-Rad Laboratories, Inc.
- Myriad Genetics, Inc
- Menarini-Silicon Biosystems
- Trovagene, Inc.
- Guardant Health, Inc.
Got a question? We've got answers. If you have some other questions, see our support center.
What is the segment’s covered for the Liquid Biopsy market?
The segment included in the Liquid Biopsy market is Application, End User, Clinical Application, Product and Service, Circulating Biomarker, Technology, Company and region.
Who are the major key vendors in the Liquid Biopsy market?
Some key players operating in the Liquid Biopsy market include Mdxhealth SA, Genomic Health, Inc., Raindance Technologies, Inc, Thermo Fisher Scientific Inc., Illumina, Inc., Biocept, Inc, Qiagen N.V., Roche Diagnostics, Bio-Rad Laboratories, Inc
What are the different forms of the report available?
We can offer several formats of the market research reports including,
• PDF
• PPT
• Spreadsheet/ Workbook
© 2020 COPYRIGHT : MARKET RESEARCH ENGINE